Abstract
Telomeres (specialized ends of eukaryotic chromosomes) shorten with each round of division in normal human cells. In contrast, cancer cells maintain their telomere length and have been defined as their most consistent attribute. It is achieved by activation of telomere maintenance mechanisms that may either involve up regulation of a specialized reverse transcriptase, telomerase (Telomerase positive, TEP) or recombination based Alternative Lengthening of Telomeres (ALT). Telomere shortening is considered as a tumor suppressor mechanism and hence the drugs to activate this mechanism are deemed anticancer agents. In this chapter we describe the basic mechanisms of telomere length maintenance and their targeting in anticancer therapy. Use of Withaferin-A as a potential anticancer drug for TEP and ALT cells is discussed. Whereas ALT cells escape the deleterious effect of telomerase inhibitors in cancer therapy, Withaferin-A kills both TEP and ALT cells effectively. Thus, Withaferin-A emerges as a promising potential candidate for cancer therapy.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Bargagna-Mohan P, Deokule SP, Thompson K, Wizeman J, Srinivasan C, Vooturi S, Kompella UB, Mohan R (2013) Withaferin A effectively targets soluble vimentin in the glaucoma filtration surgical model of fibrosis. PLoS One 8:e63881
Blackburn EH (1991) Structure and function of telomeres. Nature 350:569–573
Blackburn EH (2001) Switching and signaling at the telomere. Cell 106:661–673
Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, Harley CB, Shay JW, Lichtsteiner S, Wright WE (1998) Extension of life-span by introduction of telomerase into normal human cells. Science 279:349–352
Bryan TM, Englezou A, Gupta J, Bacchetti S, Reddel RR (1995) Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J 14:4240–4248
Bryan TM, Englezou A, Dalla-Pozza L, Dunham MA, Reddel RR (1997a) Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat Med 3:1271–1274
Bryan TM, Marusic L, Bacchetti S, Namba M, Reddel RR (1997b) The telomere lengthening mechanism in telomerase-negative immortal human cells does not involve the telomerase RNA subunit. Hum Mol Genet 6:921–926
Cao Y, Huschtscha LI, Nouwens AS, Pickett HA, Neumann AA, Chang AC, Toouli CD, Bryan TM, Reddel RR (2008) Amplification of telomerase reverse transcriptase gene in human mammary epithelial cells with limiting telomerase RNA expression levels. Cancer Res 68:3115–3123
Cesare AJ, Reddel RR (2010) Alternative lengthening of telomeres: models, mechanisms and implications. Nat Rev Genet 11:319–330
Chi F, Jong TD, Wang L, Ouyang Y, Wu C, Li W, Huang SH (2010) Vimentin-mediated signalling is required for IbeA+ E. coli K1 invasion of human brain microvascular endothelial cells. Biochem J 427:79–90
Cohen SB, Graham ME, Lovrecz GO, Bache N, Robinson PJ, Reddel RR (2007) Protein composition of catalytically active human telomerase from immortal cells. Science 315:1850–1853
Colgin L, Reddel R (2004) Telomere biology: a new player in the end zone. Curr Biol 14:R901–R902
Cong Y, Shay JW (2008) Actions of human telomerase beyond telomeres. Cell Res 18:725–732
Cong YS, Wright WE, Shay JW (2002) Human telomerase and its regulation. Microbiol Mol Biol Rev 66:407–425
Conomos D, Pickett HA, Reddel RR (2013) Alternative lengthening of telomeres: remodeling the telomere architecture. Front Oncol 3:27
Counter CM, Hahn WC, Wei W, Caddle SD, Beijersbergen RL, Lansdorp PM, Sedivy JM, Weinberg RA (1998) Dissociation among in vitro telomerase activity, telomere maintenance, and cellular immortalization. Proc Natl Acad Sci U S A 95:14723–14728
Cristofari G, Sikora K, Lingner J (2007) Telomerase unplugged. ACS Chem Biol 2:155–158
Cui ZG, Piao JL, Rehman MU, Ogawa R, Li P, Zhao QL, Kondo T, Inadera H (2014) Molecular mechanisms of hyperthermia-induced apoptosis enhanced by withaferin A. Eur J Pharmacol 723:99–107
d’Adda di Fagagna F, Reaper PM, Clay-Farrace L, Fiegler H, Carr P, Von Zglinicki T, Saretzki G, Carter NP, Jackson SP (2003) A DNA damage checkpoint response in telomere-initiated senescence. Nature 426:194–198
de Lange T (2005) Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev 19:2100–2110
Dunham MA, Neumann AA, Fasching CL, Reddel RR (2000) Telomere maintenance by recombination in human cells. Nat Genet 26:447–450
Gao R, Shah N, Lee JS, Katiyar SP, Li L, Oh E, Sundar D, Yun CO, Wadhwa R, Kaul SC (2014) Withanone-rich combination of Ashwagandha withanolides restricts metastasis and angiogenesis through hnRNP-K. Mol Cancer Ther 13:2930–2940
Giardini MA, Segatto M, da Silva MS, Nunes VS, Cano MI (2014) Telomere and telomerase biology. Prog Mol Biol Transl Sci 125:1–40
Harley CB, Futcher AB, Greider CW (1990) Telomeres shorten during ageing of human fibroblasts. Nature 345:458–460
Hartwig FP, Collares T (2013) Telomere dysfunction and tumor suppression responses in dyskeratosis congenita: balancing cancer and tissue renewal impairment. Ageing Res Rev 12:642–652
Hastie ND, Dempster M, Dunlop MG, Thompson AM, Green DK, Allshire RC (1990) Telomere reduction in human colorectal carcinoma and with ageing. Nature 346:866–868
Heiss NS, Knight SW, Vulliamy TJ, Klauck SM, Wiemann S, Mason PJ, Poustka A, Dokal I (1998) X-linked dyskeratosis congenita is caused by mutations in a highly conserved gene with putative nucleolar functions. Nat Genet 19:32–38
Henson JD, Reddel RR (2010) Assaying and investigating Alternative Lengthening of Telomeres activity in human cells and cancers. FEBS Lett 584:3800–3811
Hu J, Hwang SS, Liesa M, Gan B, Sahin E, Jaskelioff M, Ding Z, Ying H, Boutin AT, Zhang H, Johnson S, Ivanova E, Kost-Alimova M, Protopopov A, Wang YA, Shirihai OS, Chin L, DePinho RA (2012) Antitelomerase therapy provokes ALT and mitochondrial adaptive mechanisms in cancer. Cell 148:651–663
Karlseder J, Broccoli D, Dai Y, Hardy S, de Lange T (1999) p53- and ATM-dependent apoptosis induced by telomeres lacking TRF2. Science 283:1321–1325
Kaul Z, Cesare AJ, Huschtscha LI, Neumann AA, Reddel RR (2012) Five dysfunctional telomeres predict onset of senescence in human cells. EMBO Rep 13:52–59
Lee J, Hahm ER, Marcus AI, Singh SV (2015) Withaferin A inhibits experimental epithelial-mesenchymal transition in MCF-10A cells and suppresses vimentin protein level in vivo in breast tumors. Mol Carcinog 54:417–429
Levy MZ, Allsopp RC, Futcher AB, Greider CW, Harley CB (1992) Telomere end-replication problem and cell aging. J Mol Biol 225:951–960
Londono-Vallejo JA (2008) Telomere instability and cancer. Biochimie 90:73–82
Lv TZ, Wang GS (2015) Antiproliferation potential of withaferin A on human osteosarcoma cells via the inhibition of G2/M checkpoint proteins. Exp Ther Med 10:323–329
Maciel-Baron LA, Morales-Rosales SL, Aquino-Cruz AA, Triana-Martinez F, Galvan-Arzate S, Luna-Lopez A, Gonzalez-Puertos VY, Lopez-Diazguerrero NE, Torres C, Konigsberg M (2016) Senescence associated secretory phenotype profile from primary lung mice fibroblasts depends on the senescence induction stimuli. Age (Dordr) 38:26
Martinez P, Blasco MA (2010) Role of shelterin in cancer and aging. Aging Cell 9:653–666
Martinez P, Blasco MA (2011) Telomeric and extra-telomeric roles for telomerase and the telomere-binding proteins. Nat Rev Cancer 11:161–176
McDonald KL, McDonnell J, Muntoni A, Henson JD, Hegi ME, von Deimling A, Wheeler HR, Cook RJ, Biggs MT, Little NS, Robinson BG, Reddel RR, Royds JA (2010) Presence of alternative lengthening of telomeres mechanism in patients with glioblastoma identifies a less aggressive tumor type with longer survival. J Neuropathol Exp Neurol 69:729–736
Mender I, Shay JW (2015) Telomere Dysfunction Induced Foci (TIF) Analysis. Bio Protoc 5:pii: e1656
Mengual Gomez DL, Armando RG, Farina HG, Gomez DE (2014) Telomerase and telomere: their structure and dynamics in health and disease. Medicina (B Aires) 74:69–76
Munagala R, Kausar H, Munjal C, Gupta RC (2011) Withaferin A induces p53-dependent apoptosis by repression of HPV oncogenes and upregulation of tumor suppressor proteins in human cervical cancer cells. Carcinogenesis 32:1697–1705
Olovnikov AM (1971) Principle of marginotomy in template synthesis of polynucleotides. Dokl Akad Nauk SSSR 201:1496–1499
Palm W, de Lange T (2008) How shelterin protects mammalian telomeres. Annu Rev Genet 42:301–334
Passos JF, Saretzki G, Ahmed S, Nelson G, Richter T, Peters H, Wappler I, Birket MJ, Harold G, Schaeuble K, Birch-Machin MA, Kirkwood TB, von Zglinicki T (2007) Mitochondrial dysfunction accounts for the stochastic heterogeneity in telomere-dependent senescence. PLoS Biol 5:e110
Patel TN, Vasan R, Gupta D, Patel J, Trivedi M (2015) Shelterin proteins and cancer. Asian Pac J Cancer Prev 16:3085–3090
Petroni M, Sardina F, Heil C, Sahun-Roncero M, Colicchia V, Veschi V, Albini S, Fruci D, Ricci B, Soriani A, Di Marcotullio L, Screpanti I, Gulino A, Giannini G (2015) The MRN complex is transcriptionally regulated by MYCN during neural cell proliferation to control replication stress. Cell Death Differ 23:197–206
Schmitt E, Paquet C, Beauchemin M, Bertrand R (2007) DNA-damage response network at the crossroads of cell-cycle checkpoints, cellular senescence and apoptosis. J Zhejiang Univ Sci B 8:377–397
Shay JW (1997) Telomerase in human development and cancer. J Cell Physiol 173:266–270
Shay JW, Reddel RR, Wright WE (2012) Cancer and telomeres-an ALTernative to telomerase. Science 336:1388–1390
Sikora E, Bielak-Zmijewska A, Mosieniak G (2014) Cellular senescence in ageing, age-related disease and longevity. Curr Vasc Pharmacol 12:698–706
Singhapol C, Pal D, Czapiewski R, Porika M, Nelson G, Saretzki GC (2013) Mitochondrial telomerase protects cancer cells from nuclear DNA damage and apoptosis. PLoS One 8:e52989
Suman S, Das TP, Sirimulla S, Alatassi H, Ankem MK, Damodaran C (2016) Withaferin-A suppress AKT induced tumor growth in colorectal cancer cells. Oncotarget 7:13854–13864
Takai H, Smogorzewska A, de Lange T (2003) DNA damage foci at dysfunctional telomeres. Curr Biol 13:1549–1556
Thaiparambil JT, Bender L, Ganesh T, Kline E, Patel P, Liu Y, Tighiouart M, Vertino PM, Harvey RD, Garcia A, Marcus AI (2011) Withaferin A inhibits breast cancer invasion and metastasis at sub-cytotoxic doses by inducing vimentin disassembly and serine 56 phosphorylation. Int J Cancer 129:2744–2755
Um HJ, Min KJ, Kim DE, Kwon TK (2012) Withaferin A inhibits JAK/STAT3 signaling and induces apoptosis of human renal carcinoma Caki cells. Biochem Biophys Res Commun 427:24–29
van Steensel B, Smogorzewska A, de Lange T (1998) TRF2 protects human telomeres from end-to-end fusions. Cell 92:401–413
von Figura G, Hartmann D, Song Z, Rudolph KL (2009) Role of telomere dysfunction in aging and its detection by biomarkers. J Mol Med (Berl) 87:1165–1171
Vulliamy T, Beswick R, Kirwan M, Marrone A, Digweed M, Walne A, Dokal I (2008) Mutations in the telomerase component NHP2 cause the premature ageing syndrome dyskeratosis congenita. Proc Natl Acad Sci U S A 105:8073–8078
Wadhwa R, Kaul Z, Kaul SC (2016) Cell cycle checkpoints and senescence. In: Suresh ISR, Hayflick L (eds) Cellular ageing and replicative senescence. Springer, Cham, pp 145–166
Watson JD (1972) Origin of concatemeric T7 DNA. Nat New Biol 239:197–201
White LK, Wright WE, Shay JW (2001) Telomerase inhibitors. Trends Biotechnol 19:114–120
Widodo N, Kaur K, Shrestha BG, Takagi Y, Ishii T, Wadhwa R, Kaul SC (2007) Selective killing of cancer cells by leaf extract of Ashwagandha: identification of a tumor-inhibitory factor and the first molecular insights to its effect. Clin Cancer Res 13:2298–2306
Widodo N, Takagi Y, Shrestha BG, Ishii T, Kaul SC, Wadhwa R (2008) Selective killing of cancer cells by leaf extract of Ashwagandha: components, activity and pathway analyses. Cancer Lett 262:37–47
Widodo N, Priyandoko D, Shah N, Wadhwa R, Kaul SC (2010) Selective killing of cancer cells by Ashwagandha leaf extract and its component Withanone involves ROS signaling. PLoS One 5(10):e13536
Yeager TR, Neumann AA, Englezou A, Huschtscha LI, Noble JR, Reddel RR (1999) Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body. Cancer Res 59:4175–4179
von Zglinicki T, Burkle A, Kirkwood TB (2001) Stress, DNA damage and ageing - an integrative approach. Exp Gerontol 36:1049–1062
Yu Y, Katiyar SP, Sundar D, Kaul Z, Miyako E, Zhang Z, Kaul SC, Reddel RR, Wadhwa R (2017) Withaferin-A kills cancer cells with and without telomerase: chemical, computational and experimental evidences. Cell Death Dis 8:e2755
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Kaul, Z., Yu, Y., Kaul, S.C., Wadhwa, R. (2017). Withaferin-A as a Potential Candidate for Cancer Therapy: Experimental Evidence of Its Effects on Telomerase Plus and Minus Cancer Cells. In: Kaul, S., Wadhwa, R. (eds) Science of Ashwagandha: Preventive and Therapeutic Potentials. Springer, Cham. https://doi.org/10.1007/978-3-319-59192-6_9
Download citation
DOI: https://doi.org/10.1007/978-3-319-59192-6_9
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-59191-9
Online ISBN: 978-3-319-59192-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)